EyePoint Pharmaceuticals (EYPT)
(Delayed Data from NSDQ)
$10.96 USD
-0.17 (-1.53%)
Updated May 29, 2024 04:00 PM ET
After-Market: $10.95 -0.01 (-0.09%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
EYPT 10.96 -0.17(-1.53%)
Will EYPT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for EYPT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EYPT
Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics
Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know
EYPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vericel Corporation (VCEL) Q4 Earnings Beat Estimates
Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep going
Are You Looking for a Top Momentum Pick? Why EyePoint Pharmaceuticals (EYPT) is a Great Choice
Other News for EYPT
Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint reports inducement grants under Nasdaq listing rule
Maintained Buy Rating on EyePoint Pharmaceuticals Amid Positive Outlook for EYP-1901 in Wet AMD
Crocs To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday